ACE applications are now open through October 15. Join a national network committed to providing high-quality, comprehensive Ataxia care. Apply Now!
Written by Anastasiya Potapenko Edited by Asmer Aliyeva Tiny tags, big impact: new research reveals chemical tags on ataxin-3 protein influences its behavior and may contribute to brain cell death in SCA3. The genetic cause of spinocerebellar ataxia type 3 (SCA3) was discovered over three decades ago. Since then, scientists Read More…
(The Hauser Lab Back row, left to right: Linus Wiora, Stefan Hauser, Jacob Helm, Hariharan Menon, Luisa Baraban, Anabel Dickemann, Egemen Turkyilmaz. Front row, left to right: Lukas Senftleben, Natalia Vingut, Benedikt Meyer, Amelie Leonhardt, Clemens Sauter, Till Stoltenow. Not pictured: Yvonne Schelling, Melanie Kraft, Ludger Schöls) Principal Investigator: Stefan Hauser, PhD (Dr. rer. nat.) Location: German Center for Neurodegenerative Diseases, Eberhard-Karls-University of Tübingen, Tübingen, Germany Year Founded: 2023 What Read More…
When scientists test a new treatment in a clinical trial, they need a reliable way to determine whether it is safe and effective. To do this, they rely on endpoints. Endpoints are clearly defined outcomes that are measured during a trial to help determine the effects of an intervention. Clinical trials usually include several types of Read More…
Levacetylleucine, sold under the brand name Aqneursa, is an FDA-approved treatment for Niemann-Pick disease type C (NPC). It is an oral medicine, approved by the FDA in September 2024, later approved in the European Union in January 2026. Its exact mechanism of action remains unclear, but it is believed to Read More…
Written by Tala Ortiz Edited by Celeste Suart, PhD Ever wonder if experiences early in life impact symptoms of a genetic disease? Researchers found that genetics isn’t the only thing to consider in SCA6 Does the environment play a role in genetic diseases? That is the question these authors aim to answer in the context Read More…
When faced with a serious illness and no effective treatment, patients may look to experimental therapies as a last resort. Normally, patients can only access experimental drugs or other investigational medical products through clinical trials. Unfortunately, not everyone can access a clinical trial when they need it. Some live too far Read More…
Written by Ross Pelzel Edited by Dr. Larissa Nitschke New mouse studies show that mutant ataxin-2 causes dramatically more damage in older animals, revealing aging as an independent driver of disease severity In Afonso et al. 2022, the authors set out to understand how age influences the development of symptoms in spinocerebellar ataxia Read More…
Why do we need mouse models for disease research? Mouse models are crucial for understanding human diseases. They allow researchers to study how diseases develop and to test potential treatments in ways that wouldn’t be possible in humans. But how do scientists create mouse models that mimic specific diseases? One widely used Read More…
Written by Yujia Li Edited by Celeste Suart, PhD Walking test in a hospital is not the same as walking at home. Wearable sensors show that real-world walking is more variable than in the hospital. We don’t usually think about how we walk until walking starts to feel different. Walking actually takes more effort than we realize. In spinocerebellar ataxia (SCA) patients, changes Read More…
Written by Élyse Zadigue-Dubé Edited by Priscila Pereira Sena New research in SCA6 mouse models suggests boosting BDNF-TrkB signaling could change the game. Is there a world where an SCA6 diagnosis does not equate to a life sentence of motor incoordination? A study by Cook and colleagues investigated a signaling Read More…
